SCHEMBL169117

SCHEMBL169117

CC(C)Oc1cn(-c2ccc(F)cc2)nc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.51
RAB9A P51151 7/20 0.48
NPC1 O15118 6/20 0.48
LMNA P02545 1/20 0.48
KDM4E B2RXH2 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DDX3X O00571 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
UBE2N P61088 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167753 0.88 NPC1 (0.47) KMT2ARAB9ANPC1LMNAKDM4E
SCHEMBL167504 0.88 NPC1 (0.47) KMT2ARAB9ANPC1LMNAKDM4E
SCHEMBL167729 0.85 KMT2A (0.55) KMT2ARAB9ANPC1LMNAKDM4E
SCHEMBL176297 0.81 NPC1 (0.57) KMT2ARAB9ANPC1LMNAKDM4E
SCHEMBL398111 0.77 KMT2A (0.59) KMT2ARAB9ANPC1LMNAKDM4E
SCHEMBL30366986 0.76 KMT2A (0.49) KMT2ARAB9ANPC1LMNAKDM4E
SCHEMBL167952 0.74 KMT2A (0.47) KMT2ARAB9ANPC1LMNAKDM4E
SCHEMBL168201 0.72 KMT2A (0.50) KMT2ARAB9ANPC1LMNAKDM4E
SCHEMBL176199 0.72 KMT2A (0.50) KMT2ARAB9ANPC1LMNAKDM4E
SCHEMBL16578381 0.71 KMT2A (0.60) KMT2ARAB9ANPC1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103124729-B As the pharmaceutical active compounds of Axl inhibitor LEAD DISCOVERY CENTER GMBH (DE) 2016-01-20 CN disclosed
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 US disclosed
EP-2609091-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2014-11-26 EP disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 US disclosed
EP-2609091-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS Lead Discovery Center GmbH (DE) 2013-07-03 EP disclosed
CN-103124729-A Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH 2013-05-29 CN disclosed
WO-2012028332-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2012-03-08 WO disclosed
EP-2423208-A1 Pharmaceutically active compounds as Axl inhibitors Lead Discovery Center GmbH (DE) 2012-02-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS AXL, FLT3, ERBB3 KMT2A 1175/4885RAB9A 1235/4885NPC1 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.